ANGIOTENSIN II RECEPTOR BLOCKADE IN THE PREVENTION OF INTERSTITIAL EXPANSION

血管紧张素 II 受体阻断预防间质扩张

• 批准号: 7951645
• 负责人: HASSAN N IBRAHIM
• 金额: $ 3.77万
• 依托单位: UNIVERSITY OF MINNESOTA
• 依托单位国家: 美国
• 财政年份: 2008
• 资助国家: 美国
• 起止时间: 2008-12-01 至 2009-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7951645
• 关键词: Angiotensin II Receptor; Biopsy; Chronic; Chronic rejection of renal transplant; Clinical Research; Computer Retrieval of Information on Scientific Projects Database; Development; Disease; Funding; Grant; Injury; Institution; Kidney Diseases; Kidney Transplantation; Losartan; Participant; Patients; Placebo Control; Play; Prevention; Primary Prevention; Randomized; Renin-Angiotensin-Aldosterone System; Research; Research Personnel; Resources; Role; Source; System; Testing; Transplant Recipients; United States National Institutes of Health; interstitial; kidney allograft; prevent

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The renin angiotensin aldosterone system (RAAS) plays an important role in the progression of renal diseases. Blockade of this system has yielded beneficial results in retarding injury and progression in numerous intrinsic renal diseases. This system, as well as other common mechanisms of progression, operate in chronic allograft nephropathy (CAN). This project will investigate the role of the renin angiotensin aldosterone system (RAAS) in the development of chronic renal allograft nephropathy (CAN). The specific aim is to perform a 5 year randomized placebo controlled primary prevention trial in 150 patients to determine if the angiotensin II receptor blocker, Losartan, can slow or prevent corticol interstitial volume expansion and graft loss from CAN in kidney transplant recipients. The proposed study should provide both pathophysiologic rational and a practical test of therapy in a disease for which there are presently few treatment options. Participants will be admitted to the GCRC for their 5 year exit biopsy.

这个子项目是许多研究子项目中的一个 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者（PI）可能从另一个NIH来源获得了主要资金， 因此可以在其他CRISP条目中表示。所列机构为 研究中心，而研究中心不一定是研究者所在的机构。 肾素-血管紧张素-醛固酮系统（RAAS）在肾脏疾病的进展中起着重要作用。 该系统的阻断在延缓许多内源性肾脏疾病的损伤和进展方面产生了有益的结果。 该系统以及其他常见的进展机制在慢性移植物肾病（CAN）中起作用。 本研究旨在探讨肾素血管紧张素醛固酮系统（RAAS）在慢性移植肾肾病（CAN）发生发展中的作用。 具体目的是在150例患者中进行一项为期5年的随机安慰剂对照一级预防试验，以确定血管紧张素II受体阻滞剂氯沙坦是否可以减缓或预防肾移植受者中CAN引起的皮质醇间质体积扩张和移植物丢失。 拟议的研究应提供病理生理学的合理性和治疗的疾病，目前有几个治疗方案的实际测试。 受试者将进入GCRC进行5年退出活检。